DiabetesInjection Pens Market, by Product Type (Insulin Pens and Pen Needles), byUsage (Disposable and Reusable), by Distribution Channel (Hospitals Pharmacies,Retail Pharmacies, Online Medical Stores, and Diabetes Clinics), and byGeography - Global Industry Insights, Trends, Outlook, and Opportunity Analysis,2018-2026
Diabetes insulin pens areadvanced forms of prefilled insulin syringes and pen needles that are used toinject insulin in the body of patients suffering from type-1 diabetes. Thesepens usually consist of an insulin cartridge that acts as an insulin reservoirand a dial that is used to measure the exact volume of insulin that is intendedto be delivered to the patient. These cartridges and pens are available indifferent shapes and sizes and are also available in disposable andnon-disposable types. Most of the diabetes pens are incorporated with insulinpen needles that are replaceable, thin, and extremely short to reduce the paincaused during injection. Several universal pen needles are also present in themarket that fits to almost all the brands of insulin pens. These pens arehandy, easy to carry around, and can be used in home settings to provideaccuracy in dose delivery. This in turn, is increasing the demand for diabetesinsulin pens.
* The sample copy includes: Report Summary, Table ofContents, Segmentation, Competitive Landscape, Report Structure, Methodology.
Request a sample copyof this report: https://www.coherentmarketinsights.com/insight/request-sample/1156
Rising incidence of diabetes isexpected to propel the demand for insulin injection pens
Rising incidence diabetes is oneof the major factors responsible for growth of the global diabetes injectionpens market. According to the American Diabetes Association, around 30.3million of people in the U.S. suffered from diabetes, accounting for up to 9.4%of the total population in 2016. Moreover, according to the BMJ Open DiabetesResearch & Care, around 387 million people in the world suffer from diabetes,out of which around 5-10% suffer from type-1 diabetes. Various other factorsdriving growth of the market include risk of needle-stick injuries andbacterial infection caused by regular use of syringes to inject insulin and theadvancements technology related to diabetes pens, leading to development ofpainless devices for daily insulin injections. However, the availability ofinsulin patches and other substitutes for insulin delivery are expected tohamper the growth of the market.
North America to hold a dominantposition in the global diabetes injection pens market, owing to advancements intechnology development in the in diabetes pens
On the basis of region, theglobal diabetes injection pens market is segmented into North America, LatinAmerica, Europe, Asia Pacific, Middle East, and Africa. North America holds thedominant position in the global diabetes injection pens market, owing toincreasing prevalence of type-1 diabetes as well as development of advancedinjection pens by manufacturers in the region. For instance, according to theCenters of Disease Control and Prevention (CDC), around 5% of the peoplesuffering from diabetes are diagnosed with type-1 diabetes and are unable toproduce insulin naturally. This increases the demand for external insulinadministration.
Browse ResearchReport: https://www.coherentmarketinsights.com/ongoing-insight/diabetes-injection-pens-market-1156
Moreover, according to theJuvenile Diabetes Research Foundation, the healthcare burden due to type-1diabetes in the U.S. accounted for up to US$ 14 billion in 2016. Asia Pacificis expected to witness fastest growth in the market, owing to rising awarenessamong the patients as well as evolving healthcare infrastructure.
Key players are focused ondevelopment of novel products to sustain their position in the highlyconsolidated market
Key players operating in theglobal diabetes injection pens market include Novo Nordisk A/S, AstraZenecaPlc, Biocon Ltd, Eli Lilly and Company, Becton, Dickinson and Company, andJiangsu Delfu Co. Major players are consistently focused towards innovation anddevelopment in the existing technology to maintain their significance andestablish their presence in the global diabetes injection pens market. Forinstance, Novo Nordisk in 2014 introduced a new insulin injection pen deviceNovoPen Echo that was the first-ever injection pen to deliver half a unit ofinsulin, with a memory function that records last dose and the time passedsince the last injection.
Buy-Now this researchreport: https://www.coherentmarketinsights.com/insight/buy-now/1156
AboutCoherent Market Insights:
CoherentMarket Insights is a prominent market research and consulting firm offeringaction-ready syndicated research reports, custom market analysis, consultingservices, and competitive analysis through various recommendations related toemerging market trends, technologies, and potential absolute dollaropportunity.
ContactUs:
mailto:sales@coherentmarketinsights.com
U.S.Office:
Name: Mr. Shah
CoherentMarket Insights 1001 4th Ave,
# 3200Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN: +050-5539-1737
